What is the recommended dosing and administration of intravenous Risek (omeprazole) for a patient with suspected upper gastrointestinal bleeding?

Risek (Omeprazole) Infusion in Upper Gastrointestinal Bleeding

For patients with upper gastrointestinal bleeding, administer intravenous omeprazole as an 80 mg bolus followed by continuous infusion at 8 mg/hour for 72 hours after successful endoscopic hemostasis.

Dosing Protocol

The evidence-based regimen for Risek (omeprazole) in UGIB is:

• Loading dose: 80 mg IV bolus
• Maintenance: 8 mg/hour continuous IV infusion for 72 hours
• Post-infusion: Switch to oral omeprazole 40 mg twice daily for 14 days, then once daily 1, 2

This high-dose protocol significantly reduces rebleeding rates, need for surgery, and mortality compared to placebo or H2-receptor antagonists 1.

Clinical Context and Timing

After Endoscopic Therapy (Strongest Evidence)

This is where IV omeprazole has proven benefit. Following successful endoscopic hemostasis of high-risk lesions (active bleeding, visible vessel, adherent clot), the 80 mg bolus + 8 mg/hour infusion reduces rebleeding from 22.5% to 6.7% 3. The effect is most pronounced in the first 72 hours when most rebleeding occurs 3.

Before Endoscopy (Weaker Evidence)

Pre-endoscopy omeprazole can be considered but has weaker supporting evidence 1. One study showed it reduces the need for endoscopic therapy (19.1% vs 28.4%) by downgrading lesion severity 4, but this does not replace the need for urgent endoscopy and definitive hemostasis 1.

Key Clinical Distinctions

High-risk stigmata requiring this protocol:

• Active arterial spurting (Forrest IA)
• Active oozing (Forrest IB)
• Non-bleeding visible vessel (Forrest IIA)
• Adherent clot (Forrest IIB)

Low-risk lesions (clean base, flat spot) do not require high-dose IV therapy and can be managed with standard oral PPI dosing 1, 5.

Why This Specific Regimen

The continuous infusion maintains intragastric pH >6 for optimal clot stability and platelet aggregation 2. Intermittent bolus dosing (40 mg every 12 hours) is inferior—it maintains adequate pH for only 12 hours, not the full 24-hour period needed 6. The 8 mg/hour infusion after 80 mg bolus keeps pH >6 in 100% of patients over 72 hours, while bolus dosing achieves this in only 63.5% 7.

Common Pitfalls to Avoid

1. Don't use intermittent bolus dosing (40 mg Q12h) for high-risk lesions—this was shown to be suboptimal in trials 1

2. Don't skip the loading dose—the 80 mg bolus is essential for rapid pH elevation; starting with infusion alone delays therapeutic effect

3. Don't stop at 24-48 hours—most rebleeding occurs in first 72 hours, so complete the full 3-day infusion 3

4. Don't use this as a substitute for endoscopy—PPI therapy complements but does not replace endoscopic hemostasis 1

5. Don't forget oral supplementation—after 72-hour infusion, continue oral omeprazole 40 mg twice daily for 14 days to maintain healing 5, 8

Alternative Considerations

While the evidence specifically supports omeprazole and pantoprazole, guidelines suggest this is a class effect of PPIs 1. If omeprazole is unavailable, pantoprazole can be used with the same dosing regimen (80 mg bolus + 8 mg/hour infusion) 1.

Recent data suggest high-dose oral omeprazole (40 mg twice daily) may be non-inferior to IV therapy in select patients after successful endoscopic hemostasis 9, but IV remains the gold standard with strongest evidence for high-risk bleeding 5, 8.